LCB-2122
LCB-2122 is an adenosine-like nucleoside analogue bearing a C2'-stereogenic all-carbon quaternary center. LCB-2122 can prevent Doxorubicin (HY-15142A)-induced cardiomyocytes apoptosis with an IC50 of 0.5 μM and prevent Imatinib (HY-15463)-induced apoptosis. LCB-2122 can activate AMPK signaling and induce the phosphorylation of AMPK and its downstream substrate, acetyl-CoA carboxylase (ACC). LCB-2122 can reduce Doxorubicin-induced mitochondrial damage. LCB-2122 can be used for the research of heart failure.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 2210298-14-7
- Formule: C16H25ClN5O7P
- Masse moléculaire:465.83
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Voir tous les produits spécifiques à Isoform AMPK
More
Activité biologique
Chemical Information
-
CAS No. 2210298-14-7
-
Masse moléculaire 465.83
-
Formule C16H25ClN5O7P
-
SMILES
NC1=NC(Cl)=NC2=C1N=CN2[C@@H]3O[C@H](COP(OCC)(OCC)=O)[C@@H](O)[C@@]3(C)CO
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
LCB-2122 Related Classifications
HY-180575 Related Classifications
Powered by Bioz